A detailed history of Axxcess Wealth Management, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Axxcess Wealth Management, LLC holds 20,215 shares of NTLA stock, worth $265,422. This represents 0.01% of its overall portfolio holdings.

Number of Shares
20,215
Previous 19,171 5.45%
Holding current value
$265,422
Previous $429,000 3.26%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$19.72 - $27.36 $20,587 - $28,563
1,044 Added 5.45%
20,215 $415,000
Q2 2024

Aug 09, 2024

BUY
$20.02 - $27.22 $51,431 - $69,928
2,569 Added 15.47%
19,171 $429,000
Q1 2024

May 14, 2024

BUY
$23.82 - $32.8 $24,058 - $33,128
1,010 Added 6.48%
16,602 $456,000
Q4 2023

Feb 06, 2024

BUY
$23.16 - $32.34 $13,757 - $19,209
594 Added 3.96%
15,592 $475,000
Q3 2023

Nov 14, 2023

SELL
$31.62 - $45.78 $9,264 - $13,413
-293 Reduced 1.92%
14,998 $474,000
Q2 2023

Aug 08, 2023

BUY
$34.58 - $46.03 $15,180 - $20,207
439 Added 2.96%
15,291 $623,000
Q1 2023

May 03, 2023

BUY
$33.3 - $44.82 $22,577 - $30,387
678 Added 4.78%
14,852 $553,000
Q4 2022

Feb 14, 2023

SELL
$33.21 - $62.69 $130,448 - $246,246
-3,928 Reduced 21.7%
14,174 $494,000
Q3 2022

Nov 14, 2022

SELL
$53.92 - $71.7 $63,787 - $84,821
-1,183 Reduced 6.13%
18,102 $1.01 Million
Q2 2022

Aug 11, 2022

SELL
$38.49 - $76.21 $2,963 - $5,868
-77 Reduced 0.4%
19,285 $998,000
Q1 2022

Aug 11, 2022

SELL
$58.27 - $118.99 $276,141 - $563,893
-4,739 Reduced 19.66%
19,362 $1.41 Million
Q4 2021

Aug 11, 2022

BUY
$100.76 - $138.36 $2.43 Million - $3.33 Million
24,101 New
24,101 $2.85 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $998M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Axxcess Wealth Management, LLC Portfolio

Follow Axxcess Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axxcess Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Axxcess Wealth Management, LLC with notifications on news.